Dear Customer, If you experience any text readability or display issues on our website, please update your web browser to the latest version
.
See More
Dear Customer, If you experience any text readability or display issues on our website, please update your web browser to the latest version
.
See MoreDear Customer, If you experience any text readability or display issues on our website, please update your web browser to the latest version
.
This page has been recently translated and is available in French now.
Looks like you're visiting us from {countryName}.
Would you like to stay on the current location site or be switched to your location?
Multiparameter flow cytometric analysis of CD196 (CCR6) expression on Human peripheral blood leucocyte populations. Human whole blood was stained with either BD Horizon™ BUV661 Mouse IgG1, κ Isotype Control (Cat. No. 612966; Left Plot) or BD Horizon™ BUV661 Mouse Anti-Human CD196 (CCR6) antibody (Cat. No. 569509; Right Plot) at 0.5 μg/test. Erythrocytes were lysed with BD FACS™ Lysing Solution (Cat. No. 349202). The bivariate pseudocolor density plot showing CD196 (CCR6) expression (or Ig Isotype control staining) versus side light-scatter signals (SSC-A) were derived from gated events with the side and forward light-scatter characteristics of intact leucocyte populations. Flow cytometry and data analysis were performed using a BD LSRFortessa™ X-20 Cell Analyzer System and FlowJo™ software. Data shown on this Technical Data Sheet are not lot specific.
Multiparameter flow cytometric analysis of CD196 (CCR6) expression on Human peripheral blood leucocyte populations. Human whole blood was stained with either BD Horizon™ BUV661 Mouse IgG1, κ Isotype Control (Cat. No. 612966; Left Plot) or BD Horizon™ BUV661 Mouse Anti-Human CD196 (CCR6) antibody (Cat. No. 569509; Right Plot) at 0.5 μg/test. Erythrocytes were lysed with BD FACS™ Lysing Solution (Cat. No. 349202). The bivariate pseudocolor density plot showing CD196 (CCR6) expression (or Ig Isotype control staining) versus side light-scatter signals (SSC-A) were derived from gated events with the side and forward light-scatter characteristics of intact leucocyte populations. Flow cytometry and data analysis were performed using a BD LSRFortessa™ X-20 Cell Analyzer System and FlowJo™ software. Data shown on this Technical Data Sheet are not lot specific.
Multiparameter flow cytometric analysis of CD196 (CCR6) expression on Human peripheral blood leucocyte populations. Human whole blood was stained with either BD Horizon™ BUV661 Mouse IgG1, κ Isotype Control (Cat. No. 612966; Left Plot) or BD Horizon™ BUV661 Mouse Anti-Human CD196 (CCR6) antibody (Cat. No. 569509; Right Plot) at 0.5 μg/test. Erythrocytes were lysed with BD FACS™ Lysing Solution (Cat. No. 349202). The bivariate pseudocolor density plot showing CD196 (CCR6) expression (or Ig Isotype control staining) versus side light-scatter signals (SSC-A) were derived from gated events with the side and forward light-scatter characteristics of intact leucocyte populations. Flow cytometry and data analysis were performed using a BD LSRFortessa™ X-20 Cell Analyzer System and FlowJo™ software. Data shown on this Technical Data Sheet are not lot specific.
Multiparameter flow cytometric analysis of CD196 (CCR6) expression on Human peripheral blood leucocyte populations. Human whole blood was stained with either BD Horizon™ BUV661 Mouse IgG1, κ Isotype Control (Cat. No. 612966; Left Plot) or BD Horizon™ BUV661 Mouse Anti-Human CD196 (CCR6) antibody (Cat. No. 569509; Right Plot) at 0.5 μg/test. Erythrocytes were lysed with BD FACS™ Lysing Solution (Cat. No. 349202). The bivariate pseudocolor density plot showing CD196 (CCR6) expression (or Ig Isotype control staining) versus side light-scatter signals (SSC-A) were derived from gated events with the side and forward light-scatter characteristics of intact leucocyte populations. Flow cytometry and data analysis were performed using a BD LSRFortessa™ X-20 Cell Analyzer System and FlowJo™ software. Data shown on this Technical Data Sheet are not lot specific.
Multiparameter flow cytometric analysis of CD196 (CCR6) expression on Human peripheral blood leucocyte populations. Human whole blood was stained with either BD Horizon™ BUV661 Mouse IgG1, κ Isotype Control (Cat. No. 612966; Left Plot) or BD Horizon™ BUV661 Mouse Anti-Human CD196 (CCR6) antibody (Cat. No. 569509; Right Plot) at 0.5 μg/test. Erythrocytes were lysed with BD FACS™ Lysing Solution (Cat. No. 349202). The bivariate pseudocolor density plot showing CD196 (CCR6) expression (or Ig Isotype control staining) versus side light-scatter signals (SSC-A) were derived from gated events with the side and forward light-scatter characteristics of intact leucocyte populations. Flow cytometry and data analysis were performed using a BD LSRFortessa™ X-20 Cell Analyzer System and FlowJo™ software. Data shown on this Technical Data Sheet are not lot specific.
Multiparameter flow cytometric analysis of CD196 (CCR6) expression on Human peripheral blood leucocyte populations. Human whole blood was stained with either BD Horizon™ BUV661 Mouse IgG1, κ Isotype Control (Cat. No. 612966; Left Plot) or BD Horizon™ BUV661 Mouse Anti-Human CD196 (CCR6) antibody (Cat. No. 569509; Right Plot) at 0.5 μg/test. Erythrocytes were lysed with BD FACS™ Lysing Solution (Cat. No. 349202). The bivariate pseudocolor density plot showing CD196 (CCR6) expression (or Ig Isotype control staining) versus side light-scatter signals (SSC-A) were derived from gated events with the side and forward light-scatter characteristics of intact leucocyte populations. Flow cytometry and data analysis were performed using a BD LSRFortessa™ X-20 Cell Analyzer System and FlowJo™ software. Data shown on this Technical Data Sheet are not lot specific.
Any use of products other than the permitted use without the express written authorization of Becton, Dickinson and Company is strictly prohibited.
BD® CompBeads can be used as surrogates to assess fluorescence spillover (compensation). When fluorochrome conjugated antibodies are bound to BD® CompBeads, they have spectral properties very similar to cells. However, for some fluorochromes there can be small differences in spectral emissions compared to cells, resulting in spillover values that differ when compared to biological controls. It is strongly recommended that when using a reagent for the first time, users compare the spillover on cells and BD® CompBeads to ensure that BD® CompBeads are appropriate for your specific cellular application.
For optimal and reproducible results, BD Horizon Brilliant Stain Buffer should be used anytime BD Horizon Brilliant dyes are used in a multicolor flow cytometry panel. Fluorescent dye interactions may cause staining artifacts which may affect data interpretation. The BD Horizon Brilliant Stain Buffer was designed to minimize these interactions. When BD Horizon Brilliant Stain Buffer is used in in the multicolor panel, it should also be used in the corresponding compensation controls for all dyes to achieve the most accurate compensation. For the most accurate compensation, compensation controls created with either cells or beads should be exposed to BD Horizon Brilliant Stain Buffer for the same length of time as the corresponding multicolor panel. More information can be found in the Technical Data Sheet of the BD Horizon Brilliant Stain Buffer (Cat. No. 563794/) or the BD Horizon Brilliant Stain Buffer Plus (Cat. No. 566385).
Note: When using high concentrations of antibody, background binding of this dye to erythroid cell subsets (mature erythrocytes and precursors) has been observed. For researchers studying these cell populations, or in cases where light scatter gating does not adequately exclude these cells from the analysis, this background may be an important factor to consider when selecting reagents for panel(s).
The 11A9 monoclonal antibody specifically binds to CD196, which is also known as CCR6. CCR6 is a seven-transmembrane, G-protein-coupled, glycoprotein receptor that is a member of the beta chemokine receptor family. The human CCR6 gene has been mapped to chromosome 6q27. CCR6 is a receptor for the CC chemokine CCL20/MIP-3alpha/LARC/Exodus and also binds with lower affinity to and mediates responses to beta-defensin2/hBD-2. CCR6 is predominantly expressed by B lymphocytes, certain subsets of effector and memory T cells and by immature dendritic cells but not by monocytes, NK cells, or granulocytes. Skin-homing CLA (Cutaneous Lymphocyte Antigen)-positive memory T cells, Th1 cells, regulatory T cells and IL-17A-producing Th17 cells predominantly express high levels of CCR6. CCR6 mediates the trafficking of T, B, and dendritic cells to epithelial sites near the skin and mucosal surfaces during inflammatory and immunological responses. An N-terminal peptide of human CCR6 was used as an immunogen to generate the 11A9 hybridoma. The 11A9 antibody does not cross-react with human CCR1, CCR2, CCR3, CCR4, CCR5, CCR7, CCR8, CCR9, CXCR1, CXCR2, CXCR3, CXCR4 and CXCR5 receptors. This antibody is NOT a neutralizing antibody.
Please refer to Support Documents for Quality Certificates
Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described
Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims. Comparisons are not made against non-BD technologies, unless otherwise noted.
For Research Use Only. Not for use in diagnostic or therapeutic procedures.